COVID, Influenza, & RSV Resource Page
Updated: November 2024
These resources will be updated as the respiratory viral season and product availability change in Chicago and across the United States.
Reach out to [email protected] for questions regarding this content. For individual product availability, contact your local site. This content is intended as a clinical resource for prescribers at NM.
These resources will be updated as the respiratory viral season and product availability change in Chicago and across the United States.
Reach out to [email protected] for questions regarding this content. For individual product availability, contact your local site. This content is intended as a clinical resource for prescribers at NM.
COVID-19, Influenza, and RSV Frequently Asked Questions:
Co-administration of Vaccines:
Live flu vaccine considerations:
|
Which vaccines and products are available:
For patient facing information: See FDA Resources for Fall Respiratory Illness Season |
Viral Vaccine Specific FAQ Continued:
COVID-19 vACCINES
See CDC COVID Vaccine FAQ for further patient FAQs.
Disclaimer: resource links are updated frequently |
COVID-19 Vaccine Schedules Adult and Children ≥12 years old:
Special populations and FAQ:
|
COVID-19 Vaccine Schedules for Children <12 years old:
|
Influenza vACCINES
For comprehensive information, see CDC Flu Vaccine Site.
Vaccine products available at NM:
Special population FAQ:
Influenza vaccination after antivirals: inactivated vaccines are appropriate anytime.
Vaccine products available at NM:
- Regional Medical Group/Northwestern Medical Group: Fluzone (0.5 mL IM; ≥ 6 months old) and High-dose Fluzone (0.7 mL IM; ≥65 years old)
- Regional Medical Group, Northwestern Workforce, Non-Ambulatory: Fluarix (0.5 mL IM; ≥ 6 months old)
- Available at all sites: Flumist (0.2 mL intranasal 2 to 49 years old), Flucelvax (0.5 mL IM; ≥ 6 months old)
Special population FAQ:
- Pregnancy/Chronic Medical Conditions/Immunocompromised: Avoid Flumist intranasal (live vaccine)
- 6 months – 8 years: should receive two doses of the influenza vaccine for their first season
- Age 65+: high dose vaccine is recommended
- Adult solid organ transplants between 18-64 years old may receive high dose vaccine (Fluzone HD) or adjuvanted IIV (Fluad) per ACIP
- Caregivers/Contacts of high-risk patients who receive Flumist intranasal (live vaccine) should avoid severely immunocompromised patient for 7 days
- Egg allergy: can receive any flu vaccine formulation
- If previous severe allergic reaction to flu vaccine, avoid formulations that contain eggs
- In patients recovering from moderate to severe infection related illness, no flu vaccine wait period beyond illness recovery
- Self-administered intranasal influenza vaccine will not be available this season 2024-2025
- Reimbursement / patient cost:
- Medicare Part B: covered with no patient cost-sharing
- Medicaid/CHIP: covered with no patient cost-sharing
Influenza vaccination after antivirals: inactivated vaccines are appropriate anytime.
- Avoid giving Live attenuated vaccine (Flumist intranasal vaccine) after the patient received:
- Oseltamivir/Zanamivir: 48 hours before or 2 weeks after
- Peramivir: 5 days before or 2 weeks after
- Baloxavir: 17 days before or 2 weeks after
RSV VACCINE (Adults ≥ 60 Years old and Pregnancy)
RSV Vaccines for pregnant patients:
RSV Vaccines for ≥60 years old:
- Recommended by the CDC to be given in pregnancy during 32-36 weeks gestational age for the prevention of severe infant RSV infection
- Available outpatient: Abrysvo (Pfizer) 0.5 mL IM x1 dose
RSV Vaccines for ≥60 years old:
- Any patient ≥75 years old is recommended to receive an RSV vaccine
- Any patient 60-74 years old is recommended to receive an RSV vaccine with risk factors for severe disease
- Available outpatient: Abrysvo (Pfizer) 0.5 mL IM x1 dose
- Reimbursement / patient cost:
- Medicare Part D: covered with no patient cost-sharing
- Patients must have Part D for coverage. The patient may have to pay a vaccine administration fee at the time of service, but they can get reimbursed in full for this fee from their Part D plan
- Medicaid/CHIP: covered with no patient cost-sharing
- Medicare Part D: covered with no patient cost-sharing
RSV Pediatric monoclonal Antibody: Nirsevimab (Beyfortus)
For inpatient nirsevimab (Beyfortus) use, please see the NM protocol. For general recommendations and timing, see below.
RSV Pediatric mAB Product (nirsevimab):
|
RSV Pediatric mAB Product (nirsevimab) FAQ:
|
Treatment and Post-Exposure Prophylaxis (PEP):
COVID-19
Northwestern Medicine Treatment Options:
Guidelines and Resources: |
Influenza
Oseltamivir
Treatment:
Treatment and post-exposure prophylaxis for Novel Influenza A:
|
Baloxavir
Treatment and prophylaxis (regimen are the same):
|
Influenza post-exposure prophylaxis (PEP) considerations:
|
Influenza PEP High Risk per the IDSA Flu Guidelines:
|
RSV
No routine antiviral treatment for RSV is recommended at this time.